Effect of Tanreqing injection combined with Budesonide suspension for inhalation on the children with mycoplasma pneumonia

Abstract

Objective To investigate the Tanreqing injection combined with Budesonide suspension for inhalation on the children with mycoplasma pneumonia. Methods 83 children with mycoplasma pneumonia were included in the department of Pediatrics, The People′s Hospital of Fenyang City, from June 2015 to February 2017.According to the therapeutic method, all patients were divided into the inhalation treatment group(n=41)and the combined treatment group(n=42). Patients in the inhalation treatment group were treated by Budesonide suspension for inhalation.Patients in the combined treatment group treated with the Tanreqing injection combined with Budesonide suspension for inhalation.Compared the improvement of symptoms, the serum levels of solubility intercelluar adhesion molecule-1(sICAM-1)and serum monocyte chemoattractant protein-4(MCP-4), lung function(TCL)and forced vital capacity(FVC), the clinical effect, adverse reaction rate and quality of life(SF-36)score. Results The pulmonary rales, asthma, cough and fever disappearance time of the combined treatment group[(3.98±0.37)d, (3.79±1.74)d, (3.06±0.32)d and(4.52±0.27)d]were earlier than those of the inhalation treatment group[(6.03±0.64)d, (4.63±1.67)d, (5.87±1.03)d and(4.94±0.39)d], the difference was statistically significant(P<0.05). Seven days after treatment, the serum levels of sICAM-1 and MCP-4 of the combined treatment group[(181.24±18.41)μg/L and(32.39±12.28)pg/ml]were lower than those of the inhalation treatment group[(284.56±24.53)μg/L and(54.36±13.81)pg/ml], the FVC and TLC of the combined treatment group[(3.09±0.32)L and(2.46±0.18)L]were higher than those of the inhalation treatment group[(2.51±0.28)L and(1.67±0.23)L], the SF-36 scores of the combined treatment group(74.23±10.08)were higher than those of the inhalation treatment group(65.51±9.86), the difference were statistically significant(P<0.05). Conclusion Tanreqing injection combined with Budesonide Suspension for inhalation is effective in the treatment of children with mycoplasma pneumonia.It can effectively improve the lung function, symptoms and signs, reduce the serum levels of sICAM-1 and MCP-4, improve the quality of life with higher safety. Key words: Tanreqing injection; Budesonide suspension for inhalation; Mycoplasma pneumonia; Serum monocyte chemoattractant protein-4; Soluble intercellular adhesion molecule -1